Provision of laboratory services for lipid analysis in the United Kingdom

A C J Hutchesson1, M J O'Kane, R D Neely

  • 1Department of Clinical Chemistry, Royal Bolton Hospital, Bolton, UK. Andrew.Hutchesson@rbh.nhs.uk

Insights

UK clinical biochemistry labs show room for improvement in lipid analysis and reporting. Routine provision of LDL- and non-HDL-cholesterol results, alongside treatment thresholds, is recommended to align with national guidelines for coronary heart disease prevention.

Area of Science:

  • Clinical Biochemistry
  • Cardiovascular Disease Prevention
  • Laboratory Medicine

Background:

  • National guidelines in the UK aim to reduce coronary heart disease (CHD) mortality.
  • This audit evaluates the current provision of lipid analyses by UK Clinical Biochemistry services.
  • The study supports the implementation of these national guidelines.

Purpose of the Study:

  • To assess the current practices in lipid analysis provision by UK Clinical Biochemistry laboratories.
  • To identify areas for improvement in lipid testing and reporting to support CHD prevention guidelines.
  • To evaluate the interpretation and reporting of lipid profiles in clinical practice.

Main Methods:

  • Audit standards were established based on published national guidelines.
  • A questionnaire survey was distributed to all UK Clinical Biochemistry laboratories.
  • Data on lipid profile components, reporting practices, and interpretation were collected.

Main Results:

  • Routine lipid profiles including triglycerides, HDL-, LDL-cholesterol, and total:HDL cholesterol ratio were provided by 98%, 85%, 72%, and 44% of labs, respectively.
  • Only 33% and 27% of labs analyzed triglycerides and HDL-cholesterol, respectively, when requested simply to measure cholesterol.
  • Interpretation guidance and treatment thresholds were inconsistently reported, with only 20% referencing guidelines and 19 quoting secondary prevention thresholds.

Conclusions:

  • Significant scope exists for enhancing lipid analysis provision and interpretive information.
  • Laboratories should routinely report LDL-cholesterol and non-HDL-cholesterol.
  • Reports should include treatment thresholds and targets aligned with current national guidelines to aid CHD prevention.
Abstract